ALS Progression Rate Heterogeneity — mechanism and biomarker predictors

V2, Crosslink

🧫

ALS Progression Rate Heterogeneity — mechanism and biomarker predictors

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-als-prog

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# ALS Progression Rate Heterogeneity — mechanism and biomarker predictors ## Background and Rationale This longitudinal observational study addresses a critical knowledge gap in ALS research: the dramatic heterogeneity in disease progression rates among patients with similar clinical presentations. While some ALS patients experience rapid functional decline within 12 months, others maintain relative stability for 5+ years, suggesting distinct underlying molecular mechanisms. The study aims to id

METHODOLOGY NOTES

Phase 1 (Months 1-6): Recruit 400 newly diagnosed ALS patients (≤6 months from symptom onset) across 8 academic centers. Obtain informed consent and baseline assessments including ALSFRS-R, forced vital capacity, muscle strength testing, cognitive assessment (ALS-CBS), and quality of life measures. Collect blood, CSF, and urine samples for biomarker analysis. Perform whole genome sequencing and polygenic risk score calculation. Conduct baseline MRI with DTI, spectroscopy, and structural imaging. Phase 2 (Months 7-42): Monthly clinical assessments via telemedicine including ALSFRS-R, respiratory function, and adverse events. Quarterly in-person visits for biofluid collection and detailed clinical evaluation. Repeat MRI at 12 and 24 months. Analyze neurofilament light chain, phosphorylated neurofilament heavy chain, TDP-43, inflammatory cytokines, and metabolomic profiles using established assays. Phase 3 (Months 43-48): Statistical analysis using time-to-event modeling and machine learn

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.901564Z'}
summary	# ALS Progression Rate Heterogeneity — mechanism and biomarker predictors ## Background and Rationale This longitudinal observational study addresses a critical knowledge gap in ALS research: the dram
entities	{'genes': ['HNRNPA2B1/SETX/SRPK1'], 'diseases': ['ALS']}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Validate ALS Progression Rate Heterogeneity — mechanism and biomarker predictors
methodology_notes	Phase 1 (Months 1-6): Recruit 400 newly diagnosed ALS patients (≤6 months from symptom onset) across 8 academic centers. Obtain informed consent and baseline assessments including ALSFRS-R, forced vit
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.901569', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

699

Outgoing

475

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ALS Progression Rate Heterogeneity — mechanism and biomarker predictors

derives from (16)

supports (53)

💬 Discussion